Trials / Completed
CompletedNCT06192108
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 962 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orforglipron | Administered orally |
| DRUG | Dapagliflozin | Administered orally |
Timeline
- Start date
- 2024-01-10
- Primary completion
- 2025-09-26
- Completion
- 2025-09-26
- First posted
- 2024-01-05
- Last updated
- 2025-10-20
Locations
74 sites across 6 countries: United States, China, Germany, Mexico, Poland, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06192108. Inclusion in this directory is not an endorsement.